Lexicon Pharmaceuticals LXRX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's other accrued liabilities?
- Lexicon Pharmaceuticals (LXRX) reported other accrued liabilities of $1.9M in Q1 2026.
- How has Lexicon Pharmaceuticals's other accrued liabilities changed year-over-year?
- Lexicon Pharmaceuticals's other accrued liabilities decreased by 0.1% year-over-year, from $1.9M to $1.9M.
- What is the long-term trend for Lexicon Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's other accrued liabilities has grown at a 17.7% compound annual growth rate (CAGR), from $976K to $2.2M.